Efficacy of albis for the prevention of gastric mucosal injury concomitant with the use of low-dose aspirin

A prospective, randomized, placebo-controlled study

Sang Gyun Kim, Nayoung Kim, Sung Kwan Shin, In Kyung Sung, Su Jin Hong, HyoJin Park

Research output: Contribution to journalArticle

Abstract

Background/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin. Methods: Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms. Results: In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023). Conclusions: The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis.

Original languageEnglish
Pages (from-to)179-184
Number of pages6
JournalClinical Endoscopy
Volume50
Issue number2
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Aspirin
Stomach
Placebos
Peptic Ulcer
Wounds and Injuries
Gastritis
Incidence
Hyperemia
Endoscopy
Edema
Hemorrhage
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

@article{afda58aed0a54fd28a826599700b2b2b,
title = "Efficacy of albis for the prevention of gastric mucosal injury concomitant with the use of low-dose aspirin: A prospective, randomized, placebo-controlled study",
abstract = "Background/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin. Methods: Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms. Results: In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4{\%} vs. 10.0{\%}, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023). Conclusions: The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis.",
author = "Kim, {Sang Gyun} and Nayoung Kim and Shin, {Sung Kwan} and Sung, {In Kyung} and Hong, {Su Jin} and HyoJin Park",
year = "2017",
month = "3",
day = "1",
doi = "10.5946/ce.2016.031",
language = "English",
volume = "50",
pages = "179--184",
journal = "Clinical Endoscopy",
issn = "2234-2400",
publisher = "Korean Society of Gastrointestinal Endoscopy",
number = "2",

}

Efficacy of albis for the prevention of gastric mucosal injury concomitant with the use of low-dose aspirin : A prospective, randomized, placebo-controlled study. / Kim, Sang Gyun; Kim, Nayoung; Shin, Sung Kwan; Sung, In Kyung; Hong, Su Jin; Park, HyoJin.

In: Clinical Endoscopy, Vol. 50, No. 2, 01.03.2017, p. 179-184.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of albis for the prevention of gastric mucosal injury concomitant with the use of low-dose aspirin

T2 - A prospective, randomized, placebo-controlled study

AU - Kim, Sang Gyun

AU - Kim, Nayoung

AU - Shin, Sung Kwan

AU - Sung, In Kyung

AU - Hong, Su Jin

AU - Park, HyoJin

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin. Methods: Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms. Results: In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023). Conclusions: The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis.

AB - Background/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin. Methods: Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms. Results: In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023). Conclusions: The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis.

UR - http://www.scopus.com/inward/record.url?scp=85017220828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017220828&partnerID=8YFLogxK

U2 - 10.5946/ce.2016.031

DO - 10.5946/ce.2016.031

M3 - Article

VL - 50

SP - 179

EP - 184

JO - Clinical Endoscopy

JF - Clinical Endoscopy

SN - 2234-2400

IS - 2

ER -